Display options
Cite
Simovic Markovic B, Nikolic A, Gazdic M, et al. Pharmacological Inhibition of Gal-3 in Mesenchymal Stem Cells Enhances Their Capacity to Promote Alternative Activation of Macrophages in Dextran Sulphate Sodium-Induced Colitis. Stem Cells Int. 2016;2016:2640746doi: 10.1155/2016/2640746.
Simovic Markovic, B., Nikolic, A., Gazdic, M., Nurkovic, J., Djordjevic, I., Arsenijevic, N., Stojkovic, M., Lukic, M. L., & Volarevic, V. (2016). Pharmacological Inhibition of Gal-3 in Mesenchymal Stem Cells Enhances Their Capacity to Promote Alternative Activation of Macrophages in Dextran Sulphate Sodium-Induced Colitis. Stem cells international, 20162640746. https://doi.org/10.1155/2016/2640746
Simovic Markovic, Bojana, et al. "Pharmacological Inhibition of Gal-3 in Mesenchymal Stem Cells Enhances Their Capacity to Promote Alternative Activation of Macrophages in Dextran Sulphate Sodium-Induced Colitis." Stem cells international vol. 2016 (2016): 2640746. doi: https://doi.org/10.1155/2016/2640746
Simovic Markovic B, Nikolic A, Gazdic M, Nurkovic J, Djordjevic I, Arsenijevic N, Stojkovic M, Lukic ML, Volarevic V. Pharmacological Inhibition of Gal-3 in Mesenchymal Stem Cells Enhances Their Capacity to Promote Alternative Activation of Macrophages in Dextran Sulphate Sodium-Induced Colitis. Stem Cells Int. 2016;2016:2640746. doi: 10.1155/2016/2640746. Epub 2016 Jan 04. PMID: 27057168; PMCID: PMC4736319.
Copy Download .nbib Format: NLM
Share it on

Stem Cells Int. 2016;2016:2640746. doi: 10.1155/2016/2640746. Epub 2016 Jan 04.

Pharmacological Inhibition of Gal-3 in Mesenchymal Stem Cells Enhances Their Capacity to Promote Alternative Activation of Macrophages in Dextran Sulphate Sodium-Induced Colitis.

Stem cells international

Bojana Simovic Markovic, Aleksandar Nikolic, Marina Gazdic, Jasmin Nurkovic, Irena Djordjevic, Nebojsa Arsenijevic, Miodrag Stojkovic, Miodrag L Lukic, Vladislav Volarevic

Affiliations

  1. Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, 34000 Kragujevac, Serbia.
  2. Stem Cell Laboratory, Department of Biomedical Sciences, State University of Novi Pazar, Nn Vuk Karadzic Street, 36300 Novi Pazar, Serbia.
  3. Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, 34000 Kragujevac, Serbia; Spebo Medical, 16 Norvezanska Street, 16000 Leskovac, Serbia.

PMID: 27057168 PMCID: PMC4736319 DOI: 10.1155/2016/2640746

Abstract

Transplantation of mesenchymal stem cells (MSCs) reduces the severity of dextran sulphate sodium- (DSS-) induced colitis. MSCs are able to secrete Galectin-3 (Gal-3), a protein known to affect proliferation, adhesion, and migration of immune cells. We investigate whether newly synthetized inhibitor of Gal-3 (Davanat) will affect production of Gal-3 in MSCs and enhance their potential to attenuate DSS-induced colitis. Pharmacological inhibition of Gal-3 in MSCs enhances their capacity to promote alternative activation of peritoneal macrophages in vitro and in vivo. Injection of MSCs cultured in the presence of Davanat increased concentration of IL-10 in sera of DSS-treated animals and markedly enhanced presence of alternatively activated and IL-10 producing macrophages in the colons of DSS-treated mice. Pharmacological inhibition of Gal-3 in MSCs significantly attenuates concentration of Gal-3 in sera of DSS-treated animals, indicating that MSCs produce Gal-3 in this disease. In conclusion, our findings indicate that Davanat could be used for improvement of MSC-mediated polarization towards immunosuppressive M2 phenotype of macrophages.

References

  1. Pharmacology. 2007;80(4):193-9 - PubMed
  2. J Immunol. 2007 Nov 1;179(9):6255-62 - PubMed
  3. Mol Biol Rep. 2014 Aug;41(8):4977-83 - PubMed
  4. J Immunol. 2004 Feb 15;172(4):2201-9 - PubMed
  5. Stem Cells. 2010 Oct;28(10):1856-68 - PubMed
  6. Stem Cells. 2009 Mar;27(3):693-702 - PubMed
  7. PLoS One. 2013 Oct 09;8(10):e75361 - PubMed
  8. J Immunol. 2008 Aug 15;181(4):2781-9 - PubMed
  9. Clin Immunol. 2009 Jan;130(1):83-8 - PubMed
  10. Scand J Immunol. 2010 Apr;71(4):267-74 - PubMed
  11. Cell Transplant. 2013;22(8):1309-23 - PubMed
  12. Dig Dis Sci. 1993 Sep;38(9):1722-34 - PubMed
  13. Annu Rev Immunol. 2002;20:495-549 - PubMed
  14. Cell Physiol Biochem. 2015;35(3):858-65 - PubMed
  15. Am J Pathol. 2000 Mar;156(3):1073-83 - PubMed
  16. J Gastroenterol. 2011 Feb;46(2):143-52 - PubMed
  17. Clin Cancer Res. 2014 Apr 1;20(7):1823-33 - PubMed
  18. Hepatology. 2012 Jun;55(6):1954-64 - PubMed
  19. Gut. 2010 Sep;59(9):1192-9 - PubMed
  20. Immunol Res. 2012 Apr;52(1-2):100-10 - PubMed
  21. Exp Hematol. 2009 Dec;37(12):1445-53 - PubMed
  22. J Immunol. 2010 Dec 1;185(11):7037-46 - PubMed
  23. Curr Protoc Immunol. 2002 Aug;Chapter 15:Unit 15.19 - PubMed
  24. Br Med Bull. 2011;99:155-68 - PubMed
  25. J Vis Exp. 2010 Jan 19;(35):null - PubMed
  26. Expert Opin Biol Ther. 2008 Sep;8(9):1417-23 - PubMed
  27. J Immunol. 2010 Dec 1;185(11):6617-23 - PubMed
  28. Eur J Immunol. 2015 Feb;45(2):531-43 - PubMed
  29. J Immunol. 2005 Jul 1;175(1):342-9 - PubMed
  30. PLoS One. 2013 Dec 18;8(12):e83481 - PubMed
  31. Stem Cells. 2011 Oct;29(10):1549-58 - PubMed
  32. Science. 1999 Apr 2;284(5411):143-7 - PubMed
  33. Exp Hematol. 1974;2(2):83-92 - PubMed
  34. Life Sci. 2008 Dec 5;83(23-24):771-9 - PubMed
  35. Annu Rev Immunol. 2010;28:573-621 - PubMed
  36. Gastroenterology. 1990 Mar;98 (3):694-702 - PubMed
  37. Clin Exp Immunol. 1999 May;116(2):238-45 - PubMed
  38. J Exp Med. 2001 Nov 5;194(9):1207-18 - PubMed
  39. Autoimmunity. 2010 Jun;43(4):255-63 - PubMed

Publication Types